- Cumberland Pharmaceuticals (CPIX) and RedHill Biopharma Ltd. (RDHL) have entered into a strategic co-commercialization agreement for **Talicia®**, an FDA-approved oral capsule for *Helicobacter pylori* infection.  **[1087294_20251020CL01740:0]** 
- Under the agreement, a new, jointly owned company will be formed, with Cumberland providing **$4 million in investment capital** and RedHill contributing all Talicia assets.  **[1087294_20251020CL01740:0]** 
- Cumberland will manage product distribution and record sales, with the companies equally sharing net revenues; Talicia generated **$8 million in net revenues in 2024**.  **[1087294_20251020CL01740:0]** 
- Talicia is patent protected through **2042** and has **eight years of U.S. market exclusivity** under its Qualified Infectious Disease Product (QIDP) designation.  **[1087294_20251020CL01740:0]**

Cumberland Pharmaceuticals Announces Joint Commercialization Agreement for Talicia

- **Cumberland Pharmaceuticals (CPIX)** announced that its **ibuprofen injection product** received regulatory approval in **Mexico** on **October 1, 2025**.  **[1087294_20251001CL87590:0]** 
- This approval is a result of a partnership with **PiSA Farmaceutica**, which has exclusive supply and distribution rights for the product in the Mexican market.  **[1087294_20251001CL87590:0]** 
- The injectable ibuprofen is designed for intravenous delivery to manage pain and reduce fever in hospital and surgical settings, and has been shown to reduce post-operative pain and decrease the need for opioid medications.  **[1087294_20251001CL87590:0]**

CUMBERLAND PHARMACEUTICALS (CPIX)